This triple-blind, placebo-controlled trial (n=30) will investigate the effects of a sub-hallucinogenic dose of psilocybin (5 mg) combined with Imagery Re-Scripting (ImRS) on cognitive processes and self-harm behaviour in young people aged 16–25.
A randomised, triple-blind, parallel-group early-phase study (n=30) will compare a single 5 mg oral dose of psilocybin plus Imagery Re-Scripting (ImRS) versus an inert placebo capsule plus ImRS in young people with recent self-harm.
The study tests whether a low, sub-hallucinogenic psilocybin dose enhances toleration of difficult emotions and cognitive flexibility during ImRS, reducing vivid self-harm imagery and associated negative affect compared with ImRS alone.
Oral 5 mg psilocybin administered prior to Imagery Re-Scripting (ImRS).
Paired with Imagery Re-Scripting (ImRS) sessions.
Oral 25 mg MCC inert placebo capsule preceding ImRS.
25 mg microcrystalline cellulose inert capsule.